Showing results (91-100 of 100) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal diseaseMariam Lotfy Khaled, Yuan Ren, Ronak Kundalia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2022
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic MelanomaMacLean S Hall, John E Mullinax, Cheryl A Cox, et al.Biorxiv : the Preprint Server for Biology|October 28, 2024
Nanoparticles use magnetoelectricity to target and eradicate cancer cellsJohn Michael Bryant, Emmanuel Stimphil, Victoria Andre, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 3, 2025
Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine ModelsJohn Michael Bryant, Max Shotbolt, Emmanuel Stimphil, et al.Immunity|April 16, 2020
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING SignalingEslam Mohamed, Rosa A Sierra, Jimena Trillo-Tinoco, et al.Journal for Immunotherapy of Cancer|October 6, 2023
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsMacLean S Hall, Jamie K Teer, Xiaoqing Yu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic MelanomaCaitlin A Creasy, Yuzhong Jeff Meng, Marie-Andrée Forget, et al.Frontiers in Immunology|December 3, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphomaLilit Karapetyan, Joel Kuriakose, Matthew C Perez, et al.Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.Med (New York, N.Y.)|July 29, 2026
Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanomaLilit Karapetyan, Jin Xu, Kimberly Ward, et al.Pageof 10